Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure

Juan Enrique Santos-Macías; Enrique Baez de la Fuente; Arnoldo Salas-Delgado

2016, Number 3

<< Back Next >>

Gac Med Mex 2016; 152 (3)

Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure

Santos-Macías JE, Baez FE, Salas-Delgado A

Full text

How to cite this article

Language: Spanish
References: 21
Page: 334-338
PDF size: 96.25 Kb.

ABSTRACT

Background: Chronic myeloid leukemia is a myeloproliferative disease characterized by the Philadelphia chromosome and with this, the chimeric protein BCR-ABL. The first-line treatment is imatinib, a tyrosine kinase inhibitor, that has showed good results, but with a significant percentage of treatment failure. This failure has led to second-generation tyrosine kinase inhibitors as second-line treatment such as dasatinib. Objectives: The objective of the study was to evaluate the efficacy of dasatinib as second-line treatment. Material and methods: Observational, longitudinal, and retrospective study. Patients with diagnosis of chronic myeloid leukemia that presented failure to first-line treatment were included in the present study; the hematologic response was evaluated at 3, 6, and 12 months, and molecular response at 12 months of follow-up after dasatinib treatment was started. Results: Of a total of 14 patients that were included in the study, a response in the white cell count of 84.6% with a mean response at 4.7 months of follow-up was observed; also 84.6% platelet response with a mean response at 4.7 months of follow-up. Molecular response was also evaluated at a 12-month follow-up, achieving a 50% response with a mean response at 11.08 months of follow-up. A survival rate of 80% at a 12-month follow-up was observed. Conclusions: The use of dasatinib as a second-line treatment is effective in achieving a sustained hematologic response of 84.6% and a molecular response in 50%, also finding a hematologic response without achieving a total molecular response.

REFERENCES

Deininger MW. Chronic Myeloid Leukemia: An Historical Perspective. Am Soc Hematol. 2010;47:302-11.
Frazer R, Irrine AE, McMullin MF. Chronic Myeloid Leukemia in the 21st Century. Ulster Med J. 2007;76(1):8-17.
Zhang Y, Rowley JD. Chronic Myeloid Leukemia: Current Perspectives. Clin Lab Med. 2011;31:687-98.
Morales C, Torres V, Valencia JE, et al. Leucemia Mieloide Crónica: diagnóstico y tratamiento. Rev CES Med. 2010;24(1):97-108.
Khorashad JS, Deininger MWN. Selection of Therapy: Rational Decisions Based on Molecular Events. Hematol Oncol Clin N Am. 2011;25:1009-23.
Druker B, Guillot F, O’Brien S, et al. Five-Year follow-up of patients receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med. 2006;353(23):2408-17.
Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment. Hematol Oncol Clin N Am. 2011;25:981-95.
Mealing S, Bacerna L, Hawkins N, et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp Hematol Oncol. 201;2:e5.
Jabbour E, Cortes J, Kantarjian HM. Suboptimal Response to or Failure of Imatinib Treatment: What is the Optimal Strategy? Mayo Clin Proc. 2009;84(2):161-9.
Aviles-Vazquez S, Chavez-Gonzalez A, Mayoni H. Inhibidores de cinasa de tirosina (ICT): La nueva revolución en el tratamiento de la leucemia mieloide crónica. Gaceta Med de Mex. 2013;149:646-54.
Pavlovsky C, Fernandez I, Pavlosky M, et al. Diez años de seguimiento y monitoreo de 87 pacientes con leucemia mieloide crónica tratados con inhibidores de cinasa de tirosina: experiencia en FUNDALEU, Buenos Aires, Argentina. Rev Hematol Mex. 2011;12:11-6.
Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet Criteria for Failure or Suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437-44.
Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143-50.
Muller MC, Cortes J, Kim DW, et al. Dasatinib treatment of chronic-phase myeloid leukemia: analysis of responses according to preexisting BCRABL mutations. Blood. 2009;114:4944-53.
Cannel E. Dasatinib is effective in imatinib-resistant CML. The lancet. 2007;8:286.
De Angelo DJ. Managing chronic myeloid leukemia in patients intolerant to tyrosine kinase inhibitor therapy. Blood. 2012;2:e95.
Cervera E, Godínez F, Sosa R, et al. Mexican Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukemia. J Can Ther. 2013;4:747-64.
Quintar-Cardama, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia after imatinib and nilotinib (AMN 107) therapy failure. Blood. 2007;109:497-9.
Cortes J, Rousselot P, Kim D, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or –intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-13.
Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer. 2009;115(18):4136-47.
Boquimpani C, Schaffel R, Biasolu I, et al. Molecular response at 3 and 6 months after switching to a second generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leuk Lymphoma. 2014;13:1-21.